Scientists at the US Food and Drug Administration (FDA) are strongly against administering only single doses of the Moderna and Pfizer vaccines, as their efficacy has only been proven if people get two shots, The Wall Street Journal reports.
"It is essential that these vaccines be used as authorized by FDA in order to prevent Covid-19 and related hospitalizations and death," Peter Marks, director of the FDA center that oversees vaccines, told The Wall Street Journal on Saturday.
In February, some scientists and lawmakers suggested using a one-dose regimen for all coronavirus vaccines approved in the US, after certain preliminary studies showed that a single shot could be enough for some people.
"You would be flying blind to just use one dose," a senior scientist and adviser to US President Joe Biden told The Wall Street Journal, adding "If you're going to do something else other than follow the studies shown to the FDA, show me that this one-shot effect is durable."
At the end of February, the FDA announced that it had given emergency use authorization to Johnson & Johnson's single-shot vaccine. The coronavirus vaccine was the third candidate to be given FDA approval, following authorization for two-shot vaccines produced by Pfizer and Moderna.
Biden said after the approval of Johnson & Johnson's vaccine that things were still likely to get worse in terms of COVID-19 in the US as new coronavirus variants emerge.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
)